Miguel Muñoz

15PUBLICATIONS
23CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsSolid tumoursPsychopharmacology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jan 25, 2026
Aprepitant increases the antitumor activity of chemotherapy by chemosensitizing breast cancer cells.

Prema Robinson, Marisa Rosso, Yousef Zamil

|Nov 27, 2025
The Involvement of the Peptidergic Systems in Breast Cancer Development.

Manuel L Sánchez, Prema Robinson, Zal Italia

|Oct 16, 2025
A Dual-Purpose Approach for an Anti-Emetic NK1R Antagonist as a Chemosensitizer and Cardioprotectant in a Preclinical Model of Triple-Negative Breast Cancer.

Miguel Muñoz, Rafael Coveñas, Younus Zuberi

|Feb 13, 2025
Radiotherapy Plus the Neurokinin-1 Receptor Antagonist Aprepitant: A Potent Therapeutic Strategy for the Treatment of Diffuse Intrinsic Pontine Glioma.

Miguel Muñoz, Marisa Rosso

|Nov 14, 2023
The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.

Rafael Coveñas, Francisco D Rodríguez, Prema Robinson

|Oct 14, 2023
Substance P and Neurokinin-1 Receptor System in Thyroid Cancer: Potential Targets for New Molecular Therapies.

Inmaculada Isorna, Miguel Ángel González-Moles, Miguel Muñoz

Pageof 3

Frequent Collaborators

7 joint publications

Rafael Coveñas

3 joint publications

Marisa Rosso

2 joint publications

Tan Hoang

2 joint publications

Miguel Ángel González-Moles